Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Langsenlehner, T; Renner, W; Gerger, A; Hofmann, G; Thurner, EM; Kapp, KS; Langsenlehner, U.
Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients.
Radiother Oncol. 2011; 98(3):387-393
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Autor/innen der Med Uni Graz:
Gerger Armin
Hofmann Günter
Kapp Karin S.
Langsenlehner Tanja
Langsenlehner Uwe
Renner Wilfried
Thurner Eva-Maria
Gendermonitor:
Altmetrics:

Abstract:
Background and purpose: Polymorphisms in genes responsible for DNA damage signaling and repair might modulate DNA repair capacity and, therefore, affect cell and tissue response to radiation and influence individual radiosensitivity. The purpose of the present prospective investigation was to evaluate the association of single nucleotide polymorphisms in XRCC1 with radiation-induced late side effects in prostate cancer patients treated with radiotherapy. Material and methods: To analyze the role of XRCC1 polymorphisms for late toxicity 603 participants from the Austrian PROCAGENE study treated with three-dimensional conformal radiotherapy were included in the present investigation. Three non-synonymous candidate polymorphisms in the X-ray repair cross-complementing group 1 (XRCC1) gene (Arg194Trp; Arg280His; Arg399Gln) were selected and determined by 5-nuclease (TaqMan) assays. Results: Within a median follow-up time of 35 months, 91 patients (15.7%) developed high-grade late toxicities (defined as late bladder and/or rectal toxicity RTOG >= 2). In a Kaplan-Meier analysis, carriers of the XRCC1 Arg280His polymorphism were at decreased risk of high-grade late toxicity (p = 0.022), in multivariate analysis including clinical and dosimetric parameters as potential confounders the XRCC1 Arg280His polymorphism remained a significant predictor for high-grade late toxicity (HR = 0.221,95% CI 0.051-0.956; p = 0.043). No significant associations were found for the remaining polymorphisms. Conclusions: We conclude that the XRCC1 Arg280His polymorphism may be protective against the development of high-grade late toxicity after radiotherapy in prostate cancer patients. (C) 2011 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 98 (2011) 387-393
Find related publications in this database (using NLM MeSH Indexing)
-
DNA-Binding Proteins - genetics
Humans -
Male -
Polymorphism, Single Nucleotide -
Prostatic Neoplasms - genetics Prostatic Neoplasms - radiotherapy
Radiation Tolerance - genetics
Radiotherapy, Conformal - adverse effects
Rectum - radiation effects
Time Factors -
Urinary Bladder - radiation effects

Find related publications in this database (Keywords)
Radiotherapy
Late toxicity
Predictive factors
DNA repair
XRCC1 polymorphisms
© Meduni Graz Impressum